Osteoarthritis Market Research Report – Forecast Till 2032

Osteoarthritis Market Research Report Information By Type (Hip Osteoarthritis, and Spinal Osteoarthritis), By Diagnosis (Imagining, and Joint Fluid Analysis), By Treatment (Medication, Surgery, Therapy), By End-User (Hospitals, and Medical Institutes) and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

ID: MRFR/Pharma/1078-HCR | 90 Pages | Author: Rahul Gotadki | March 2024         

Osteoarthritis Market Speak to Analyst Request a Free Sample

Global Osteoarthritis Market Overview


The Osteoarthritis Market Size was valued at USD 4.3 billion in 2022 and is projected to grow from USD 4.69 Billion in 2023 to USD 10.27 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.1% during the forecast period (2023 - 2032). The growing awareness about the disease and the availability of advanced treatment options drive the market growth for osteoarthritis treatment. The increasing demand for minimally invasive and non-surgical treatments, such as physical therapy, drugs, and injections, also contributes to the market growth of the osteoarthritis. These are just a few of the market drivers that are driving the market.


Osteoarthritis Market Overview1


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Osteoarthritis Market Trends



  • Increased demand for certified Osteoarthritis products to propel market growth


The geriatric population and the growing incidence of osteoarthritis also contribute to the market's growth. The increasing awareness about the benefits of non-invasive pain management options and the availability of technologically advanced products are expected to drive osteoarthritis market growth further. The market is expected to grow with the development of novel and more effective pain management products and treatments and with increasing research and development investments by companies. Thus, this factor is driving the market CAGR.


Personalized medicine can help to better manage OA by tailoring treatment plans based on an individual's unique characteristics and underlying biology, thus optimizing the benefits of therapy and minimizing any adverse effects. The use of biomarkers for diagnosis and prognosis in OA, along with advancements in technology and the development of new drugs, is expected to drive the growth of the personalized medicine market for osteoarthritis treatment.


In addition, the development of targeted therapies, such as small molecule inhibitors and biologics, is expected to drive the market growth of osteoarthritis. The increasing need for non-invasive and minimally invasive surgical procedures, and the use of regenerative therapies, such as stem cell and platelet-rich plasma therapy, is anticipated to drive the market growth of osteoarthritis. The sedentary lifestyle are also contributing to the market growth. Thus, it is anticipated that this aspect will accelerate market revenue of Osteoarthritis.


Osteoarthritis Market Segment Insights


Osteoarthritis Type Insights


The market for osteoarthritis segmented, based on type, includes hip osteoarthritis, spinal osteoarthritis. The arabica segment held the majority share in 2022 in the market of Osteoarthritis data. The increasing adoption of sedentary lifestyles, coupled with increasing obesity rates, is also driving the spinal osteoarthritis market growth. The growing market for minimally invasive surgical procedures and the development of new treatments are also boosting the market growth.


Osteoarthritis Diagnosis Insights


The Osteoarthritis market segmentation, based on diagnosis, includes imaging and joint fluid analysis. The imaging segment dominated the market growth osteoarthritis in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Imaging technologies play a crucial role in the diagnosis and management of osteoarthritis. Radiography is the most commonly used imaging modality in osteoarthritis research and clinical management, while MRI and ultrasound are used in atypical cases or when the rapid progression of symptoms is observed.


Figure 2:  Osteoarthritis Market, by Diagnosis, 2022 & 2030 (USD Billion)


Osteoarthritis Market, by Diagnosis


Source: Secondary Research, Primary Research, MRFR Database and Analyst Review


Osteoarthritis Treatment Insights


The market data of Osteoarthritis, based on treatment, includes medication, surgery, and therapy. The medication segment dominated the osteoarthritis market revenue in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the rise in the adoption of nonsteroidal anti-inflammatory drugs (NSAIDs), the increase in the number of new product launches, and the increase in the number of prescriptions. Due to the increase in the prevalence of osteoarthritis, advancements in R&D for developing new viscosupplementation agents, and government initiatives to support research in the healthcare sector.


Osteoarthritis End-User Insights


The market segment of Osteoarthritis, based on end-user, includes hospital, and medical institutes. The hospital segment dominated the market revenue of osteoarthritis in 2022 and is projected to be the faster-growing segment during the forecast period. The hospital segment was the major contributor in 2022 and is expected to maintain its lead due to government initiatives and the rise in the prevalence of osteoarthritis.


Osteoarthritis Regional Insights


By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Osteoarthritis market accounted for USD 1.96 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. Additionally, the rising awareness of osteoarthritis and increasing investment in research and development activities by pharmaceutical companies are contributing to the market growth of osteoarthritis in North America. The high adoption of advanced medical technologies and the existence of major regional players are expected to boost market growth. New product development, partnerships, partnerships, expansions, mergers, and acquisitions are the main strategies used by the organisations in the market.


Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 3:  OSTEOARTHRITIS MARKET SHARE BY REGION 2022 (%)OSTEOARTHRITIS MARKET SHARE BY REGIONSource: Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe Osteoarthritis market accounts for the second-largest market share. Europe is expected to continue to rapidly grow the market for osteoarthritis due to the factors mentioned, such as the high prevalence of knee osteoarthritis, increase in the number of drug approvals, presence of key players in the market, availability of advanced research activities for drug development, and increase in the number of clinical studies to evaluate the safety and efficacy of drugs. Moreover, UK market of Osteoarthritis held the largest market share, and the Germany market of Osteoarthritis was the fastest growing market in the region.


Asia Pacific Osteoarthritis Market is expected to grow at the fastest CAGR from 2022 to 2030. The Asia-Pacific market is expected to witness considerable development during the forecast period due to a large patient pool, an increasing geriatric population, and healthcare spending. The rise in the number of osteoarthritis patients and the growing demand for advanced osteoarthritis treatments are also anticipated to propel the market growth in the region. In addition, increasing initiatives taken by the government to develop the healthcare sector, and growing number of clinical trials and studies conducted in the region are some of the factors expected to contribute to the growth of the Asia-Pacific market of Osteoarthritis. Further, the China market of Osteoarthritis held the largest market share, and the India market of Osteoarthritis was the fastest growing market in the region.


Osteoarthritis Key Market Players & Competitive Insights


Major market players are spending a lot of money on R&D to increase their product lines, which will help the market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the osteoarthritis industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.


One of the primary business strategies adopted by manufacturers in the osteoarthritis industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, osteoarthritis industry has provided medicine with some of the most significant benefits. The osteoarthritis market major player such as Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp & Dohme Corp.


GSK is a leading player in the pharmaceutical industry, specializing in developing and manufacturing innovative medicines, vaccines, and consumer healthcare products. The company operates ly and has a presence in over 150 countries. GSK has a strong portfolio of prescription drugs and consumer healthcare products, including treatments for respiratory diseases, HIV, cancer, and vaccines. It also has a significant research and development program, focusing on developing new treatments for unmet medical needs. In 2020, GSK launched its new offering Voltaren in the US.


Flexion Therapeutics is focused on developing and commercializing local therapies for musculoskeletal conditions, particularly osteoarthritis, a common form of arthritis. The company is based in Burlington, Massachusetts, USA. In 2017, Flexion Therapeutics got approval from the FDA for their new offering in the US ZILRETTA.


Key Companies in the market of Osteoarthritis includes



Osteoarthritis Industry Developments


September 2022: StemOne, the off-the-shelf cell therapy product by Alkem Laboratories, received regulatory approval from the Drug Controller General of India (DCGI) for its launch in India. This product is being launched in collaboration with Stempeutics, which aims to treat knee osteoarthritis, a degenerative joint disease.


August 2022: Shionogi & Co., Ltd. and Grünenthal GmbH have entered into a licensing agreement to jointly market and commercialize injectable resiniferatoxin in Japan. Resiniferatoxin is a pipeline product developed by Grünenthal, and it is intended to treat pain caused by osteoarthritis of the knee. The licensing agreement will allow the companies to bring the product to market in Japan, offering a new treatment option for patients with knee osteoarthritis.


August 2022: Novartis obtained approval from the US FDA for LNA043 for treating knee osteoarthritis and is being developed as a first-in-class disease-modifying treatment for OA.


September 2021 Duexis, a combination of ibuprofen and famotidine, is utilized to relieve pain and inflammation associated with rheumatoid arthritis and osteoarthritis. Lupin Limited's launch of generic Duexis in the US expands the availability of treatment options for patients suffering from these conditions.


Osteoarthritis Market Segmentation


Osteoarthritis Type Outlook (USD Billion, 2018-2030)



  • Hip Osteoarthritis

  • Spinal Osteoarthritis


Osteoarthritis Diagnosis Outlook (USD Billion, 2018-2030)



  • Imaging

  • Joint Fluid Analysis


Osteoarthritis Treatment Outlook (USD Billion, 2018-2030)



  • Medication

  • Surgery

  • Therapy


Osteoarthritis End User Outlook (USD Billion, 2018-2030)



  • Hospitals

  • Medical Institutes


Osteoarthritis Regional Outlook (USD Billion, 2018-2030)




  • North America



    • US

    • Canada




  • Europe



    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe




  • Asia-Pacific



    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific




  • Rest of the World




    • Middle East




    • Africa




    • Latin America





Report Scope:

Report Attribute/Metric Details
Market Size 2022 USD 4.3 billion
Market Size 2023 USD 4.69 billion
Market Size 2032 USD 10.27 billion
Compound Annual Growth Rate (CAGR) Β 9.1% (2023-2032)
Base Year 2022
Market Forecast Period 2023-2032
Historical Data 2018 - 2021
Market Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered Type, Diagnosis, Treatment, End-User and Region
Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp & Dohme Corp.
Key Market Opportunities Asia-pacific countries
Key Market Dynamics Growing aging population ly




Frequently Asked Questions (FAQ) :

The Osteoarthritis market size was valued at USD 4.3 Billion in 2022.

The market is projected to grow at a CAGR of 9.1% during the forecast period, 2023-2032.

North America had the largest share in the market

The key players in the market are Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp & Dohme Corp.

The key players in the market are Abbott, Novartis AG, Pfizer Inc., Eli Lilly and Company., ABIOGEN PHARMA S.p.A, Merck Sharp & Dohme Corp.

The spinal osteoarthritis category dominated the market in 2022.

The hospitals had the largest share in the market.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid